Welcome to the e-CCO Library!

P593: A national database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. E. Stellingwerf*1, W. A. Bemelman1, G. R. D'Haens2, C. Y. Ponsioen2, C. J. Buskens1

Created: Friday, 22 February 2019, 9:41 AM
P593: Biologicals and small molecule combotherapies: promising experience in refractory IBD patients
Year: 2022
Source: ECCO'22
Authors: JuilleratMSc, P.(1);Martinho-Grueber, M.(1);Michetti, P.(2);
Created: Friday, 11 February 2022, 3:56 PM
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Briot1*, P. Faure2, A.L. Parmentier1, C. Gay1, C. Trang3, M. Nachury4, S. Viennot5, R. Altwegg6, P. Bulois7, L. Thomassin8, M. Serrero9, P. Ah Soune10, C. Gilletta11, L. Plastaras12, M. Simon13, X. Dray14, L. Caillo15, E. Del Tedeco16, V. Abitbol17, C. Zallot18, T. Degand19, V. Rossi20, G. Bonnaud21, D. Colin22, B. Morel23, J.B. Danset24, B. Winkfield25, J. Filippi26, A. Amiot27, A. Attar28, A. Bourreille29, J.C. Grimaud9, A. Blain30, L. Peyrin Biroulet18, L. Vuitton1

Created: Thursday, 21 February 2019, 9:14 AM
P593: Hospital resource use and cost associated with first-line anti-TNF therapy in patients with IBD in the UK: comparison of subcutaneous (adalimumab) and intravenous (infliximab) therapies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hickey J.1, Keshav S.2,3, Gaugris S.4, Arasaradnam R.*5

Created: Wednesday, 20 February 2019, 10:36 AM
P593: Impact of immunomodulating treatment modalities, active smoking and (repeated) COVID19 vaccination on S-antibody seroconversion in IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Geldof, J.(1)*;Truyens, M.(2);Sabino, J.(3);Ferrante, M.(3);Lambert, J.(4);Lapeere, H.(4);Hillary, T.(5);Van Laethem, A.(5);de Vlam, K.(6);Verschueren, P.(6);Padalko, E.(7);Lobaton, T.(2);Vermeire, S.(3);
Created: Friday, 14 July 2023, 11:05 AM
P593: Ustekinumab for the treatment of perianal Crohn’s disease. A real-world experience in a Spanish hospital
Year: 2021
Source: ECCO'21 Virtual
Authors: Algara San Nicolas, M.(1);Masedo Gonzalez, A.(1);Gomez Gomez, G.J.(1);Yela San Bernardino, C.(1);Casis Herce, B.(1);Martinez Montiel, M.P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P594 Increased levels of stress, anxiety and depression among patients with CD and UC
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Laoudi1, D. Papalouka2, M. Gkizis1, G. Kokkotis1, N. Perlepe1, I. Vlachogiannakos3, I. Papakonstantinou2, G. Bamias1

Created: Thursday, 30 January 2020, 10:12 AM
P594: Bowel ultrasound is useful in predicting relapse in patients with Ulcerative Colitis in remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Maeda, M.(1)*;Sagami, S.(1,2);Tashima, M.(1);Yamana, Y.(1);Karashima, R.(1,2);Miyatani, Y.(1);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
Created: Friday, 14 July 2023, 11:05 AM
P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Panés1*, D. García-Olmo2, A. Parfionovas3, C. Agboton4, J.M. Khalid5

Created: Thursday, 21 February 2019, 9:14 AM
P594: Predictors of non-response to repeated faecal microbiota transplantation in patients with therapy refractory ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Blesl*1, F. Rainer1, P. Wurm1, M. Durdevic1, W. Petritsch1, H. Wenzl1, F. Baumann-Durchschein1, A. Posch1, A. Streit1, G. Gorkiewicz1, H-P. Gröchenig2, P. Kump1, C. Högenauer1

Created: Friday, 22 February 2019, 9:41 AM
P594: Ustekinumab treatment effectiveness in clinical practice – a multicentre retrospective review of long-term outcomes in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rowan C.R.*1, Alakkari A.2, Moran C.3, O'Connell J.4, Cullen G.1, Mulcahy H.1, O'Morain C.2, McNamara D.2, Leyden J.5, MacMathuna P.5, O'Toole A.3, Patchett S.3, McKiernan S.4, Kevans D.4, Doherty G.A.1, Ryan B.2

Created: Wednesday, 20 February 2019, 10:36 AM
P594: Utilisation of anti-TNF agents in phlegmonous Crohn’s disease: an Australian tertiary referral centre experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Chiu, L.(1);Digby-Bell, J.(2);Seah, J.(1,3);Melton, S.(1,4);Taylor, K.(1,2);Sparrow, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P594: Vedolizumab dose intensification does not always improve treatment persistence.
Year: 2022
Source: ECCO'22
Authors: Hilley, P.(1);Peterson, A.R.(1);Wong , D.(1,2);Hine, K.(1);Srinivasan, A.(1);Choy, M.C.(1,2);De Cruz, P.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P595 Feasibility and performance of a fully automated endoscopic disease severity grading tool for ulcerative colitis using unaltered multisite videos
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Stidham1,2, H. Yao3, S. Bishu1, M. Rice1, J. Gryak3, H.J. Wilkins4, K. Najarian2,3,5

Created: Thursday, 30 January 2020, 10:12 AM
P595: Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD–GO-SWIBREG
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Eriksson1, D. Bergemalm1*, L. Vigren2, L. Nilsson3, I. Visuri1, H. Hjortswang4, R. Udumyan5, S. Almer6, M. Seddighzadeh7, E. Hertervig8, P. Karlén3, H. Strid9, J. Halfvarson1, The GO-SWIBREG study group

Created: Thursday, 21 February 2019, 9:14 AM
P595: Early medical therapy and risk of subsequent perianal fistula development among paediatric patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Adler*1,2, C. C. Lin3, S. Gadepalli2,4, K. Dombkowski2

Created: Friday, 22 February 2019, 9:41 AM
P595: Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Freitas, M.(1,2,3);Capela, T.(1,2,3);Macedo Silva, V.(1,2,3);Arieira, C.(1,2,3);Cúrdia Gonçalves, T.(1,2,3);Dias de Castro, F.(1,2,3);Moreira, M.J.(1,2,3);Cotter, J.(1,2,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P595: The influence of vitamin D on expression of cytokines mRNA in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Leskova Z.*1, Krajčovičová A.1, Šoltys K.2, Stuchlík S.2, Šturdík I.1, Koller T.1, Huorka M.1, Hlavatý T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P595: Time of Therapeutic Drug Monitoring of infliximab during induction and its relationship with clinical remission in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Muñoz-Villafranca, C.(1);Arreba , P.(1);Gomez, M.(2);Ispizua Madariaga, N.(1)*;Buendia, L.(1);Lopez, M.L.(1);Ugarte, A.(1);de la Fuente, I.(1);Prado, N.(1);Irusta, L.(1);Jimenez, M.A.(1);Santa Cruz, M.(1);Gonzalez, M.(1);Bilbao, A.(3);Ortiz de Zárate, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P595: Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients
Year: 2022
Source: ECCO'22
Authors: Van Moorsel, F.(1,2);Deben, D.(3);Creemers, R.(4,5);Winkens, B.(6);Pierik, M.(7);Bus, P.(8);Simsek, M.(9);de Boer, N.(9);van Bodegraven, A.(4);Wong, D.(3);
Created: Friday, 11 February 2022, 3:56 PM